Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3504]

Fedratinib improves spleen and symptom responses with promising survival...

Dr Andrew Kuykendall - Moffitt Cancer Center, Tampa, USA

Fedratinib improves spleen and symptom responses with promising survival outcomes in MDS/MPN and CNL ( Dr Andrew Kuykendall - Moffitt Cancer Center, Tampa, USA )

177Lu-rosopatamab plus standard of care shows manageable safety and favourable...

Dr Pedro Barata - University Hospitals Seidman Cancer Center, Cleveland, USA

177Lu-rosopatamab plus standard of care shows manageable safety and favourable tumour targeting in mCRPC ( Dr Pedro Barata - University Hospitals Seidman Cancer Center, Cleveland, USA )

Darovasertib plus crizotinib improves outcomes in HLA-A2–negative metastatic...

Dr Marlana Orloff - Thomas Jefferson University Hospital, Philadelphia, USA

Darovasertib plus crizotinib improves outcomes in HLA-A2–negative metastatic uveal melanoma ( Dr Marlana Orloff - Thomas Jefferson University Hospital, Philadelphia, USA )

Early-onset gastrointestinal cancers show more advanced disease and wider...

Dr Jessica Paulus - Ontada, Boston, USA

Early-onset gastrointestinal cancers show more advanced disease and wider racial survival gaps ( Dr Jessica Paulus - Ontada, Boston, USA )

Xaluritamig plus abiraterone shows promising anti-tumour activity with...

Dr David Pook - Monash Health, Melbourne, Australia

Xaluritamig plus abiraterone shows promising anti-tumour activity with manageable safety in chemotherapy-naïve mCRPC ( Dr David Pook - Monash Health, Melbourne, Australia )

Tarlatamab improves brain metastases control and survival compared to chemo in...

Dr Giannis Mountzios - The University of Athens, Athens, Greece

Tarlatamab improves brain metastases control and survival compared to chemo in SCLC ( Dr Giannis Mountzios - The University of Athens, Athens, Greece )

Mezigdomide plus carfilzomib and dexamethasone delays disease progression in R...

Dr Paul Richardson - Dana-Farber Cancer Institute, Boston, USA

Mezigdomide plus carfilzomib and dexamethasone delays disease progression in R/R multiple myeloma ( Dr Paul Richardson - Dana-Farber Cancer Institute, Boston, USA )

Aspirin use linked to improved survival in endometrial cancer

Dr Zachary Gentry - The Ohio State University, Columbus, USA

Aspirin use linked to improved survival in endometrial cancer ( Dr Zachary Gentry - The Ohio State University, Columbus, USA )

Daraxonrasib nearly doubles survival in previously treated metastatic...

Dr Brian Wolpin - Dana-Farber Cancer Institute, Boston, USA

Daraxonrasib nearly doubles survival in previously treated metastatic pancreatic cancer ( Dr Brian Wolpin - Dana-Farber Cancer Institute, Boston, USA )

Lorlatinib delivers 7-year progression-free survival and durable brain control...

Prof Tony Mok - Chinese University of Hong Kong, Ma Liu Shui, Hong Kong

Lorlatinib delivers 7-year progression-free survival and durable brain control in ALK+ NSCLC ( Prof Tony Mok - Chinese University of Hong Kong, Ma Liu Shui, Hong Kong )

Apalutamide plus ADT improves surgical outcomes in high-risk prostate cancer

Dr Adam Kibel - Dana-Farber Cancer Institute, Boston, USA

Apalutamide plus ADT improves surgical outcomes in high-risk prostate cancer ( Dr Adam Kibel - Dana-Farber Cancer Institute, Boston, USA )

Abemaciclib shows benefit in dedifferentiated liposarcoma

Dr Mark Dickson - Memorial Sloan Kettering Cancer Center, New York, USA

Abemaciclib shows benefit in dedifferentiated liposarcoma ( Dr Mark Dickson - Memorial Sloan Kettering Cancer Center, New York, USA )

More from ecancer